ARA-290 (Cibinetide) (10mg)

ARA-290 (also called Cibinetide) is an 11-amino-acid peptide derived from a specific region of erythropoietin (EPO) called helix B. It was designed to keep the tissue-protective and anti-inflammatory activity of EPO while stripping out the red-blood-cell-stimulating activity that makes full-length EPO unsuitable for many research applications. It binds a receptor complex called the innate repair receptor (IRR), which is only expressed on injured or stressed tissue.

Full-length EPO has two distinct activities: it stimulates red-blood-cell production (via the classical EPO receptor homodimer), and it protects damaged tissues from further injury (via the innate repair receptor). ARA-290 was engineered to bind only the second receptor, so it does not raise haematocrit. This is the central feature researchers find useful — it lets the tissue-protection and anti-inflammatory pathways be studied in isolation.

The IRR is a heterodimer made up of the EPO receptor (EPOR) paired with the beta-common receptor (CD131). Unlike the classical EPOR homodimer found on erythroid progenitor cells, the IRR is only expressed on tissues under stress — sites of injury, inflammation, or hypoxia. Activating it triggers anti-inflammatory and pro-survival signalling locally, without systemic haematopoietic effects.

Published preclinical work has examined ARA-290 across models of small-fibre neuropathy, ischaemia-reperfusion injury, diabetic complications, and metabolic inflammation. A 28-day human trial in patients with sarcoidosis-associated small-fibre neuropathy reported improvements in patient-reported pain and autonomic symptom scores. The compound has remained an investigational research molecule and has not received regulatory approval for therapeutic use in any jurisdiction we are aware of.

ARA-290 is supplied as a lyophilised powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial along the inside wall and gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 8–12 weeks. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilised ARA-290 vials at -20°C, away from light and moisture. After reconstitution, refrigerate at 2–8°C and use within 8–12 weeks. Do not freeze the reconstituted solution.

ARA-290 (10mg) is available through Aussie Peptides with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia — no customs delays. Each batch undergoes third-party analysis and the Certificate of Analysis is available to view in our CoA Library.

ARA-290 (Cibinetide) (10mg) is currently available on pre-order at Aussie Peptides, with dispatch expected between 16 September 2026 and 18 September 2026. ARA-290 (Cibinetide) (10mg) is priced at $89.99 per vial at Aussie Peptides. All orders ship domestically within Australia, and batch CoAs are available in our CoA library.